Your current web browser is outdated. For best viewing experience, please consider upgrading to the latest version.

Donation - Other Level

Please use the quantity box to donate any amount you wish. Sign Up to Donate

Contact

Send a question or comment using the form below. This message may be routed through support staff.

Email Article

Password Reset Request

Register


Add a topic or expert to your feed.

Following

Follow Experts & Topics

Stay on top of our work by selecting topics and experts of interest.

Experts
Topics
Project
On The Ground
ERROR
Main Error Mesage Here
More detailed message would go here to provide context for the user and how to proceed
ERROR
Main Error Mesage Here
More detailed message would go here to provide context for the user and how to proceed

Manhattan Institute

search
Close Nav
Share this commentary on Close

MI Responds: Obama's Latest Steps on Precision Medicine

commentary

MI Responds: Obama's Latest Steps on Precision Medicine

July 7, 2016
Health PolicyDrug DevelopmentAffordable Care Act

"MI Responds" features real-time commentary from Manhattan Institute scholars on breaking news and developing issues. Click here to view more.

The President’s Precision Medicine Initiative has the potential to be his most significant health care legacy, helping to develop tailored health solutions to millions of Americans.

But much of it will depend on the policies of his successor: and both Secretary Clinton and Donald Trump have called for price controls on new medicines. If we don’t encourage companies to make the large, long-term investments needed to develop precision medicines, sharing data and building databases won’t be enough to deliver new cures.

______________________

Paul Howard is a senior fellow and director of health policy at the Manhattan Institute

Saved!
Close